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Kidney transplantBK virus-associated nephropathy (BKVN) occurs in up to 5% of kidney transplants and is a signiﬁcant cause of
graft loss. Four major subtypes of BKV have been described, with the vast majority of individuals persistently
infected with BKV Type I (N80% of the population). Sequencing of BKV isolates subcloned from BKVN patients
revealed a high percentage of variants in the urine (40%) in the VP1 subtyping region. In vitro analysis of
several viral variants revealed that all variants recovered from the urine of BKVN patients produced
infectious viral particles and were replication competent in cell culture while some of the variants induced
cytopathic changes in infected cells when compared to the major BKV subtype, VP1 Type I. These results
suggest that rare BKV VP1 variants are more frequently associated with disease and that some variants could
be more cytopathic than others in renal transplant recipients.ce, Center for Neurovirology,
ERB, 3500 N. Broad Street,
on).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Serological studies indicate that more than 80% of the population
worldwide is infected with the polyomavirus, BKV (Egli et al., 2009;
Gardner, 1973; Portolani et al., 1974). Rates of seropositivity are
signiﬁcantly related to age with BKV seroprevalence reaching 91% at
5–9 years of age (Knowles et al., 2003) and falling to 71% at age 50–59
years (Egli et al., 2009). Primary infection with BKV is usually
unapparent, although in some instances viral infection has been
accompanied by mild respiratory illness or urinary tract disease
(Goudsmit et al., 1981; Padgett et al., 1983). During primary infection,
viremia occurs and the virus spreads to several organs of the infected
individual,where it remains in a latent state. Results fromvirion isolation
studies have established that the kidney is themain site of BKV latency in
healthy individuals (Chesters et al., 1983; McCance, 1983). Occasionally
BKV can reactivate in healthy individuals and virus becomes readily
detectable in the urine by PCR (Polo et al., 2004). In the context of
immunosuppression, reactivation of latent BKV in the kidney causes
renal stenosis and interstitial nephritis in approximately ﬁve percent of
kidney transplant patients (Ramos et al., 2009; Trofe et al., 2004).The latter disease, which is known as BKV-associated nephropathy
(BKVN) or polyomavirus-associated nephropathy (PVAN), is a serious
inﬂammatory complication in renal transplant recipients that can
progress to allograft failure. The factors that control the balance
between the state of viral latency and reactivation in the human host
are closely tied to the individual's immune status. While most adults
have antibodies against BKV, this humoral immune response is
apparently unable to prevent virus reactivation and development of
disease. It is not clear whether immunosuppressive regimens used by
renal transplant patients to prevent rejection have a direct effect on
viral reactivation and the course of BKV lytic infection or whether they
act indirectly by affecting the host cell or by their effect on the
immune system. Many risk factors for BKVN have been proposed
including male gender, older age, negative serostatus of the patient
before transplantation, donor positive serostatus, prior acute rejection
episodes, HLA mismatches, and rearrangement in the non-coding
control region (NCCR) of BKV (for reviews of risk factors evaluated,
see Ramos et al., 2009; Trofe et al., 2006). BKVN is a complex disease
that most likely results from the interaction of multiple donor, organ
and recipient risk factors.
Currently, there are no FDA approved non-nephrotoxic agents for
the treatment of BKVN and no drugs with anti-viral activity
speciﬁcally directed at the polyomavirus life cycle are available for
prophylaxis or therapy. Reduction in immunosuppression has been
successful for control of BKVN in a handful of centers (Brennan et al.,
313S. Tremolada et al. / Virology 404 (2010) 312–3182005; Ginevri et al., 2007), but the risk of acute graft rejection may
prohibit such a reduction in many patients. The anti-viral effect of
anecdotal treatments which have been attempted has been difﬁcult to
assess due to the concomitant reduction in immunosuppression, their
broad inclusion criteria, small sample sizes and lack of data in
randomized trials. As such, optimal prophylaxis or therapy for BKVN
has not been established to date (Ramos et al., 2009).
The humanpolyomavirusBKbelongs to the Polyomaviridae, a family
of small, non-enveloped DNA viruses with an icosahedral capsid of
45 nm in diameter that contains a circular double-stranded genome of
approximately 5 kb (Imperiale and Major, 2007). The capsid is
comprised of the late proteins, VP1, VP2 and VP3, which are produced
by alternative splicing of the viral late gene transcript. VP1, which is the
major capsid protein, is present on the surface of the capsid and is
responsible for receptor binding to host cells. In addition, VP1 is highly
immunogenic, is the target of neutralizing antibody and is required for
virion assembly and hemagglutination of red blood cells. Four distinct
serotypes of BKV have been previously determined by hemagglutina-
tion inhibition, namedSubtypes I–IVby Jin et al (1993). Genetic analyses
of VP1 sequences have determined that the serotyping region contains a
variable region of the BKV genome between nucleotides 1744 and 1812
(amino acids 61 to 83). Antibodies to this region of the virus capsid are
capable of neutralization and prevent the virus from interacting with
host cells. A homologymodel of BKVVP1 built using SWISS-MODEL and
predicted structures of other polyomavirus proteins present in public
databases suggests that three major loop structures within the BC loop
are likely responsible for interaction of the virus capsid with sialic acid
containing receptors on host cells (Dugan et al., 2005). Interestingly, the
BC loop corresponds to the serotyping region of BKVVP1 responsible for
the diversity between the four subtypes. Closer examination of the four
BKV subtypes reveals amino acids varying in charge, and while some of
the amino acid substitutions between Types I and IV are conserved
changes in charge, there are several non-conserved substitutions as
well. Genotype I is the most frequent in the normal human population
worldwide (80%)with Type IV is the secondmost frequent (15%),while
genotypes II and III are infrequentlydetected innormal adults (Takasaka
et al., 2004). Several evolutionary studies using phylogenic analysis of
the four subtypes have determined that the BK virus has co-evolved
with humans (Krumbholz et al., 2008; Luo et al., 2009; Yogo et al., 2009;
Zheng et al., 2007).
In addition to Types I–IV, other rearrangements or variants in the
VP1 subtying region have been reported in BKVN patients (Baksh
et al., 2001). DNA sequencing of the VP1 genotyping region from
kidney biopsies derived from patients affected by BKV interstitial
nephritis underlined the existence of “hot spots” of nucleotide
polymorphisms, and in most of the cases the follow-up of the patients
showed that this region was not stable over time. It has been
suggested that these “hot spots” for mutations could represent an
advantage for the virus in escaping the host immune surveillance
(Randhawa et al., 2002). In some cases, the variability predicted
changes in the amino acid sequence with potential consequences for
the secondary and tertiary structure of the protein. Recent in vitro
studies on variant subtypes show amino acid substitutions can alter
the ability of virus to interact with host cells suggesting that the
variantsmay have functional relevance (Dugan et al., 2007). However,
two recent studies in which the BKV subtyping was performed by PCR
ampliﬁcation found no correlation between BKV subtypes and the
development of BKV infection in renal transplant recipients (Krautk-
tkrämer et al., 2009; Tremolada et al., 2010).
In an attempt to investigate the role of BKV genotypes in the
pathogenesis of BKVN, we examined their distribution in renal
transplant recipients at the time of diagnosis with BKVN through
the subcloning and sequencing of the subtyping region of the VP1
gene (nt.1633-2009). Analysis of the sequences obtained revealed a
number of BK virus VP1 polymorphisms in BKVN patients which
resulted in amino acid substitutions not found in the four establishedBKV genotypes. These polymorphic genotypes, together with the
uncommon genotype IV, were much more frequent in BKVN patients
in comparison to their distribution in the normal population. Analysis
of selected variants in a cell culture system suggests they are
replication competent and could contribute to the cytopathic effects
seen in BKVN.
Results
All 20 KTX patients were diagnosed with BKVN by renal transplant
biopsy and a positive ISH for BK virus as described in Materials and
methods within a mean of 12.9 months after renal transplantation
(range 3 to 38 months), which is typical for most transplant centers
(Ramos et al., 2009). As summarized in Table 1, patients who
developed BKVN had a range of underlying disease responsible for
loss of renal function in their native kidneys. All patients had serum
BKV loads N1×103 and 19 (95%) had urine BKV loads N1×106 with
the exception of one patient who had a urine BKV load of 5.15×105 at
diagnosis though subsequent urine viral loads exceeded 1×106. These
viral loads are consistent with reported diagnostic thresholds for
BKVN (Hirsch et al., 2002, 2005).
Compared to United Network for Organ Sharing national trans-
plant data as well as center-speciﬁc data from the University of
Cincinnati and The Christ Hospital (based on OPTN data, October 10,
2007), the demographics of the patient population developing BKVN
were similar to the national proﬁle in terms of recipient age, gender,
race, type of transplant (deceased donor, living related or unrelated
donor), transplant number and chronic kidney disease etiology with
the exception of a higher percentage of male BKVN patients (80%
compared to national average of 60% of kidney transplant recipients
during this same time period). Patients typically received induction
therapy with anti-thymocyte globulin, basiliximab or daclizumab and
began double or triple immunosuppressive regimens at the time of
transplantation that were a combination of mycophenolate plus
tacrolimus or sirolimus, with or without prednisone at the time of
BKVN diagnosis.
It is unclear whether a particular subtype or a variant of BKV plays
a role in the development or the pathogenesis of BKVN. To address
this question, the VP1 polymorphic serotyping region was ampliﬁed,
subcloned and sequenced from the urine of renal transplant patients
at the time of diagnosis with BKVN. A minimum of three individual
subcloneswere sequenced from each patient sample. The prototypical
BKV Dunlop strain, Type I, represents the predominant subtype
detected in the human populations and accounts for greater than 80%
of all circulating virus while Type IV is found in approximately 15% of
the normal human population, and Types II and III are relatively rare
(Knowles, 2001; Takasaka et al., 2004; Yogo et al., 2009). In contrast,
in the patient population with BKVN, only 11/20 (55%) had Type I
alone in urine and only 1/20 (5%) had Type IV alone (Table 1). The
remaining patients, 8/20 (40%), had variant subtypes of virus that had
amino acid substitutions not corresponding to Type I–IV sequence as
the only detected subtype(s) in the urine (2/20) or present in
conjunctionwith either Type I (4/20) or Type IV (2/20). This indicates
that BKVN patients often have rare subtypes of BK virus present in
urine. No correlation was seen between viral subtype and viral load in
the serum or urine nor could any correlation be made between the
viral subtype and clinical outcome.
In order to determine the potential contribution of different
subtypes and polymorphisms observed in our patients toward the
pathogenesis of BKVN, subtypes I, II, III and IV as well as several viral
variants were subcloned. Only variants which harbored changes that
resulted in amino acid substitutions were selected. In addition, BK
virus amino acid substitutions that appeared in more than one patient
were selected in order to ensure that any ﬁndings might have a
broader implication. In order to ensure that no sequences outside of
the viral subtyping region could be responsible for observed
Table 1
BKV subtypes and amino acid substitutions detected in urine of patients with polyomavirus-associated nephropathy at time of diagnosis.
Patient Viral subtype No. clones/
total sequence
Underlying disease Months
to PVAN
SCr
(mg/dL)
BKV viral load
Serum Urine
1 I 3/3 Type I diabetes 7 1.8 5.33×106 1.86×108
2 I 3/3 Unknown 11 2.1 4.43×104 4.28×106
3 I 2/3 Type I diabetes 8 1.6 2.59×106 7.08×108
I/K69R* 1/3
4 I 1/3 Membranous 15 2.2 1.02×107 9.82×108
I/D75N* 2/3 Glomerulonephritis
5 I 3/3 Type 2 diabetes 7 1.9 9.94×105 9.71×108
6 IV 1/3 Focal segmental 14 3.6 1.65×105 1.70×108
IV/E77Q 1/3 Glomerulosclerosis
IV/A72V/E77Q 1/3
7 I 3/3 Unknown 9 1.5 5.88×105 1.03×109
8 I 1/5 Type I diabetes 3 1.6 2.73×105 1.91×107
III 1/5
II/III/N62H* 3/5
9 IV 3/3 Glomerulonephritis 4 2.4 4.08×104 3.17×106
10 I 3/3 Systemic lupus erythematosus 13 1.8 1.26×104 4.35×108
11 I/K69R* 3/3 Unknown 31 1.5 3.93×106 1.46×109
12 I 1/5 Polycystic kidney disease 19 2.2 3.73×104 5.15×105
I/R83G 1/5
I/E73D/E82N* 2/5
IV 1/5
13 I 3/3 Infectious glomerulonephritis 6 2.6 1.99×106 4.53×109
14 I 3/3 Hypertension 6 1.9 1.28×106 1.68×1010
15 I 3/3 IgA nephropathy 9 2.0 4.81×106 3.42×108
16 I/K69N 1/3 Hypertension 18 2.6 6.49×105 7.78×109
I/A72/V 1/3
I/P81H 1/3
17 IV 1/3 Type I diabetes 38 2.0 1.81×104 1.08×109
IV/N62H* 2/3
18 I 3/3 Unknown 6 1.8 1.53×105 7.22×109
19 I 3/3 Glomerulonephritis 11 1.9 8.07×105 4.59×109
20 I 3/3 IgA nephropathy 23 1.9 4.71×104 7.11×109
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containing the entire genome of the Dunlop subtype (Type I) such
that they replaced the analogous region of the VP1 sequence. The
unique BamHI and EcoRI sites ﬂanking the VP1 subtyping region were
used in this procedure so that except for the introduced subtyping
changes, the sequence of viral genome remained intact and the coding
region of VP1 was unaltered. The amino acid sequences of the
subtyping region (amino acids 61–83 of VP1) of the BKV subtypes I–IV
and variants used in this study are shown in Table 2. The overall
percentages of patients with clones of Types I through IV and variants
in this study are shown in Table 3.
Virus stocks were prepared from these cloned isolates by
transfection/infection with the linear BK viral genome excised from
the plasmids by digestionwith BamHI. The digested genomic DNAwas
then directly transfected into Cos-7 cells using liopofectamine reagent
(InVitrogen). Viral stocks were generated in Cos-7 cells because of
their high-level expression of SV40 T-antigen, which acts in trans atTable 2
BKV subtypes I–IV and mutants used in the present study.
Amino acid (VP1) 61 62 63 64 65 66 67 68 69 70
consensus D N L R G Y S L K L
I E F
II
III Q H
IV N D R
I/K69R E F Ra
I/K69M/D75N E F Mb
I/E73D/E82N E F
II/III/N62H Hb Q H
a Amino acid substitution at a subtying position with an amino acid encoded by another
b Amino acid substitution at a subtyping position resulting in a mutation not seen in sub
c Amino acid substitution at a non-subtyping position resulting in a mutation in a regionthe BKV non-coding control region (NCCR) to upregulate viral DNA
replication, and perhaps other steps in the virus life cycle, for efﬁcient
virus production. Cultures were then expanded when conﬂuent and
harvested when signs of cytopathic effects (CPE) were evident in the
cultures. The VP1 subtyping regions of all the viral stocks were
sequenced to ensure no substitutions or mutations had occurred.
Subtypes II, III and IV and the selected variants were cultured in vitro
and viral stocks of each virus strain were prepared. No difﬁculties
were experienced in culturing of the variants that would suggest
defective packaging or assembly of viral particles during preparation
of the viral stocks.
Since the VP1 subtyping region is responsible for the hemagglu-
tinating activity of BKV, it is possible that variations in the amino acid
sequence in this region might lead to differences in the efﬁciency of
hemagglutination. This might lead to changes in the apparent titer of
viral stocks measured by hemagglutination when comparing different
subtypes of BKV. In order to address this possibility, we measured the71 72 73 74 75 76 77 78 79 80 81 82 83
S/T A E N A F E S D S P D R
S D S E
T D K
S
T T
S D S E
S Nb S E
S Dc D S Nb
T D K
subtype.
types I through IV.
conserved within subtypes I through IV.
Table 3
Percentage of patients with clones of Types I through IV and mutants in this study of 20
patients and 64 clones.
Predominant
type
Position Substitution Charge No.
patients
Clones % Total
Type I 15 38 59.4
Type II 0 0 0
Type III 1 1 1.5
Type IV 4 6 9.4
K69Ra Subtyping Type IV conserved 5 4 6.3
K69N Subtyping Mutant + to neutral 1 1 1.5
A72V Conserved Mutant conserved 2 2 3.2
D75Na Subtyping Mutant − to non-
polar
1 2 3.2
P81H Conserved Mutant non-polar
to +
1 1 1.5
R83G Subtyping Mutant + to − 1 1 1.5
E73Da Conserved Mutant conserved 1 2 3.2
E82Na Subtyping Mutant − to no
charge
1 2 3.2
N62Ha Subtyping Mutant no charge
to +
2 5 7.8
E77Q Subtyping Mutant − to no
charge
1 2 3.2
a Amino acid mutations examined in this study.
Fig. 1. Comparison of BK virus variants by Q-PCR, HA and Western blotting. BK virus
Types I–IV and several variants with amino acid substitutions detected in patients with
BKVN were cloned, viral stocks produced in vitro and independently titered by Q-PCR
and HA assay. The 1×108 viral particles were subjected toWestern blot analysis for the
major capsid protein, VP1. (A) Immunoblotting of 1×108 BK virus particles as
determined by Q-PCR shows production of equivalent amounts of VP1 in the major
subtype, Type I, in comparison with BK virus Type IV and BKVN variants. (B)
Immunoblotting of 1×108 particles as determined by HA assay shows similar levels of
VP1 in all viral subtypes analyzed. (C) Quantitation of VP1 levels determined in Panel A
(Q-PCR) versus Panel B (HA units or HAU) presented as percent relative intensity when
compared to the level of VP1 detected in BK virus Type I by Q-PCR, i.e., level of VP1 in
Panel A, Lane 1 set at 100%.
315S. Tremolada et al. / Virology 404 (2010) 312–318titer of viral stocks by both Q-PCR and by hemagglutination and then
quantitated the amount of VP1 by immunoblotting (Fig. 1). As shown
in the Western blot in Fig. 1A, one million BK virus particles as
determined by Q-PCR shows production of equivalent amounts of VP1
for Type I BKV when compared to Type IV BKV and the BKVN variants.
Similarly, one million BK virus particles as determined by hemagglu-
tination assay using the conversion factor of 1 HA units = 10,000
plaque forming units (pfu) (as determined previously by others,
Miller et al, 1983; Flaegstad and Traavik, 1987) showed similar levels
of VP1 by Western blot for the viral stocks of all subtypes analyzed
(Fig. 1B). Quantitation of the levels of VP1 in Figs. 1A and B was
performed by densitometry, and the results are presented as percent
relative intensity when compared to the levels of VP1 detected by Q-
PCR for Type I BKV, i.e., all values are normalized to Fig. 1A, lane 1
being set as 100% (Fig. 1C). Good agreement was found in the levels of
VP1 measured by Q-PCR (black columns) as compared the levels of
VP1 measured by hemagglutination assay (grey columns).
The viruses were compared in parallel using the Vero cell line
which is derived from African green monkey kidney cells. Vero cells
were chosen for this study since they are able to support productive
replication of BKV and have been widely used for basic research of the
virology of BKV (Acott et al., 2006). In particular, the morphology and
growth pattern of the of Vero cells enabled clear detection of
cytopathic effects (CPE) during the course of infection. Vero cell
cultures were infected with the different viral stocks as described in
Materials and methods. Cultures were infected with comparable
numbers of infectious units of each variant per cell, and signs of CPE
and cell death (detached, ﬂoating cells) were scored and supernatant
was collected for Q-PCR analysis over time. Cytopathic effects (CPE)
were not observed in any of the cultures before 15 days but some CPE
was observed at 26 days in cultures infected with BKV Type I (Fig. 2B)
and a signiﬁcant CPE for BKV Type IV (Fig. 2C). For the variants I/
E73D/E82N (Fig. 2D) and I/K69R (Fig. 2H), the CPE was much more
pronounced at 26 days when compared to BKV Type I (Fig. 2B). The
time course of development of CPE in I/K69R-infected cells is shown
in Figs. 2E–H. Some cells showed vacuolization that increased over
time. It is interesting that Type I, which is the most prominent
subtype, showed the least signs of CPE or cell death. Q-PCR results on
supernatants from the infected cells (Fig. 2I) showed that all viral
stocks replicated in Vero cells. Interestingly, some of the rare isolates
and rare variants (Type IV, I/E73D/E82N and I/K69R) were able toreplicate as efﬁciently as Type I, and yet they caused more CPE even
though they replicated at the same level as Type I. These data suggest
that virus DNA production may not be a comprehensive way to
measure viral ﬁtness and pathogenic potential. Similar results were
obtained with the CV-1 monkey kidney cell line and human renal
proximal tubule epithelial cells (data not shown).Discussion
Four subtypes of BKV exist in the human population. Our data
indicate distinct differences in viral subtype distribution in virus
isolated from BKVN patients versus that found in the normal
population. The vast majority of the population worldwide (N80%)
is persistently infected with the Type I subtype of BKV, with Type IV
being the second most frequent (15%), and genotypes II and III being
Fig. 2. In vitro replication of BK virus variants in CV-1 and Vero monkey kidney cell lines demonstrates viability of all variants despite differences in replication proﬁle and cytopathic
effects. Representative phase-contrast images of Vero cells uninfected (Panel A) versus infected with BK virus Type I (Panel B), Type IV (Panel C) and mutant Type I/E73D/E82N on
day 26 post-infection demonstrates signiﬁcant cytopathic effects in subtypes IV and I/E73D/E82N when compared with Type I. Representative images of Vero cells infected with
Type I/K69R on days 15 (Panel E), 20 (Panel F), 23 (Panel G) and 26 (Panel H) post-infection demonstrate progression in cytopathic effects over the course of infection. (I)
Replication of BK virus Types I–IV and BKVN variants in Vero monkey kidney cells as determined by Q-PCR.
316 S. Tremolada et al. / Virology 404 (2010) 312–318only infrequently detected in normal adults (Knowles, 2001; Takasaka
et al., 2004; Yogo et al., 2009). Here we report that, in urine samples
from a patient population with BKVN, Type I was relatively
underrepresented and 40% showed the presence of variant subtypes
of virus that had amino acid substitutions not corresponding to Type
I–IV sequence, i.e., BKVN patients often have rare subtypes of BKV
present in their urine. Since the subtype region is involved in
hemagglutination and the binding of virions to the viral receptors
present on the surface of host cells, this immediately suggested that
the differences might be of pathological importance. Our understand-
ing of the importance of these differences is hampered by a lack of
fundamental understanding of the molecular events that may be
mediated by subtype differences. Therefore, we assessed the
virological and molecular biological characteristics of some VP1
subtypes from patient samples in vitro and in a cell culture model.
The subtyping region lies within the major VP1 capsid protein
which is prominently displayed on the surface of BKV virions.
Differences in VP1 within the subtyping region could thus lead to
important differences in infectivity between the subtypes. Addition-
ally, differences in VP1 may be important at late stages of the lytic
cycle infection when viral capsids are being assembled. Indeed, we
have found that the VP1 subtypes migrate with different mobilities on
polyacrylamide gels, even in the presence of SDS, suggesting major
structural dissimilarities between these VP1 isoforms which may
affect capsid assembly and structure. However, sequence analysis of
substitutions in this region do not predict differences in common
post-translational modiﬁcations such as phosphorylation. In addition,
all viruses were viable in our cell culture assay system andquantitation of viral particles by Q-PCR was highly similar among
variants as well as in comparison with HA assay results suggesting
that capsid assembly and virion formation is not signiﬁcantly affected.
Analysis of the four BKV subtypes and four variant subtypes, after
cloning the subtype region into the same BKV genomic background
(Dunlop), revealed that they are all capable of infecting and
replicating in a cell culture model system (Vero cells). Two of the
Type I variants (I/E73D/E82N and I/K69R) replicated strongly while
the other two variants (II/III/N62H and I/K69M/D75N) replicated
more slowly. Interestingly, the I/E73D/E82N and I/K69R variants
produced a signiﬁcantly greater CPE than the Type I subtype,
suggesting that these variations may be an important correlate of
pathogenesis in BKVN. Further studies are needed to address the
relationship of subtype variations and BKVN pathogenesis.Conclusions
In conclusion, our data show that polymorphisms in the VP1
subtype region of virus are frequently found in the urine of patients
with BKVN. These polymorphisms strongly inﬂuenced the growth of
the virus in cell culture and the ability of the virus to induce cytopathic
effects. This suggests the possibility that one or more subtype variants
may contribute to BKV pathogenesis and that variants may contribute
renal allograft damage and subsequent inﬂammatory response. In
future studies, it may be possible to delineate amino acid residues that
are crucial for viral growth and pathogenesis, which might facilitate
the development of new therapeutic options for BKVN.
317S. Tremolada et al. / Virology 404 (2010) 312–318Materials and methods
Patient population and accessioning of clinical samples
All patients receiving renal transplants performed at The University
of Cincinnati andTheChristHospitalswere offeredenrollment in an IRB-
approved prospective BKVN study at time of BKVN diagnosis from June
2001until December 2005.All patientswere followeduntil June1, 2007.
Renal biopsies were performed in patients presenting with an
unexplained rise in serum creatinine of at least 20% (SCr). BKVN was
diagnosed by lightmicroscopic viral cytopathic changes consistentwith
BKVN and conﬁrmed by in situ hybridization (ISH) for BK virus on
parafﬁn embedded sections of renal allograft biopsies (Drachenberg
et al., 2001). Samplesof bloodandurinewere collected inparallelwithin
1 week of BKVN diagnosis, stored at 4 °C and accessionedwithin 24 h of
collection. Serum was separated from whole blood by centrifugation,
aliquotted and stored at –70 °C until use. Unspun urine was resus-
pended, aliquotted and stored at –70 °C until use.
Quantitative PCR (Q-PCR) of clinical samples and viral cultures
BK virus loads in patient serum and urine were quantitated by real-
time PCR for the presence of BKV DNA essentially as described (Leung
et al., 2002; Radhakrishnan et al., 2004). DNA extracted from 40 μl of
serum or plasma using the QiaAmp DNA mini kit (Qiagen) or 5 μl of
unspun urine was analyzed in triplicate. For virus replication assays,
DNA extracted from cell culture pellets using the QiaAmp DNAmini kit
was analyzed in triplicate. Q-PCR was performed using primers which
represent nt 2511-2531 and 2605-2586 of the VP1 sequence of the
Dunlop strain (Type I) of BK virus. Each 50 μl Q-PCR reaction contained
200 and 400 nM of forward (5′-AGTGGATGGGCAGCCTATGTA-3′) and
reverse primers (5′-TCATATCTGGGTCCCCTGGA-3′) and 200nMof BKV-
speciﬁc probe (nt 2546-2578) (5-FAM-AGGTAGAAGAGGT-
TAGGGTGTTTCATGGCACA-BHQ1-3′) in 1× Taqman Universal Master
Mix (Perkin Elmer). Cycling conditions were 45 cycles of annealing at
60 °C for 60 s anddenaturationat95 °C for 15 s. PlasmidDNAcontaining
the BK virus Type I (Dunlop) genome served to generate a standard
curve against which samples were analyzed using iCycler software
(BioRad). All Q-PCR results were calculated as copies per milliliter.
Sequence ampliﬁcation and analysis
BKV isolates were ampliﬁed and cloned from free virus present in
urine collected frompatients byDNAextraction using theQiaAmpmini-
DNA extraction kit. Five microliters of eluate from urine samples was
ampliﬁedby traditionalPCRusingprimersﬂanking the subtyping region
of VP1 fromnt 1630 tont 1956 to generate a 327-bpPCRproduct, i.e., 5′-
CAAGTGCCAAAACTACTAAT (327-1) and 5′-TGCATGAAGGTTAAG-
CATGC (327-2) (Jin et al., 1993), which was subcloned into the vector
pCR2.1 using the TA Cloning Kit (Invitrogen, Carlsbad, CA) in order to
increase efﬁciency of the ligation. Individual colonies were propagated,
inserts were veriﬁed by restriction enzyme digestion with XbaI and
HindIII and samples were individually sequenced using T7 and T3
primers.
Cloning of plasmids used in this study
The entire genome of BKV Type I was cloned from pBKV (ATCC),
which contains Dunlop strain (Type I) in the BamHI site of pBR322.
The BKV Type I genomic DNA was isolated from pBKV by digestion
with BamHI, puriﬁcation by gel electrophoresis, re-ligation, then
digestion with PstI. BKV Type I was then ligated into the PstI site of
pUC19 after ﬁrst removing the pUC19 BamHI and EcoRI sites by
restriction digestion with BamHI and EcoRI followed by modiﬁcation
with Klenow. The resulting plasmid, pBKV-DUN, was used as a
backbone for replacing the BamHI/EcoRI Type I VP1 fragment withVP1 sequences isolated from TA cloning vectors containing BamHI/
EcoRI genome fragments ampliﬁed from patient samples as described
above. All constructs were veriﬁed by direct sequencing.
Virus production
Cos-7 cells that express the SV40 T-antigen were used for
production of viral stocks. Plasmid DNA was digested with BamHI to
release the entire genome in linear form, then Cos-7 cells were
transfected with the linearized DNA to initiate infection. After
transfection, cells were washed and re-fed with DMEM containing
2% FBS. Cells were subcultured for approximately 3 to 4 weeks until
CPE were observed, then adherent and non-adherent cells were
collected and pelleted. The cell pellet was then freeze–thawed and
treated with 0.25% deoxycholic acid to help release the virus. The
cellular debris was then pelleted and the virus-containing superna-
tant was aliquotted and stored at −80 °C until needed. In the case of
low-titer stocks, the virus-containing supernatant was used to re-
infect a fresh monolayer of Cos-7 cells and the process was then
repeated. Viral titer was determined by Q-PCR and HA assay and
integrity of the VP1 subtyping region was veriﬁed by direct
sequencing of denatured viral DNA.
Virus replication assay
Vero or CV-1 African green monkey kidney cells were obtained
from the American Type Cell Culture (ATCC). Cells were infected with
BKV stocks at a multiplicity of infection of 1 based on Q-PCR results,
i.e., one plaque forming unit (pfu) equivalent. Infection was
performed in serum-free medium for 3 h at 37 °C. After infection,
cells were washed and re-fed with DMEM supplementedwith 5% fetal
calf serum. Supernatants were collected from uninfected and infected
cells at 5, 10, 15, 20 or 26 days post-infection for DNA extraction and
cells were subcultured in parallel. Viral DNA was quantitated by
Q-PCR.
Hemagglutination assay
Virus was titered by hemagglutination (HA) assay by serial
dilution in PBS and incubation with 100 μl of 0.5% human type O
erythrocytes in Alsever's buffer after which the samples were allowed
to settle for 4h at 4 °C before reading. The BK virus titers were
expressed as the reciprocal of the ﬁnal dilution in which hemagglu-
tination of the red blood cells was observed (Hamilton et al., 2000).
Western blot analysis
Immunoblotting was performed on isolated viral particles resus-
pended in TNN buffer containing 50 mM Tris (pH 7.5), 150 mM NaCl
and 0.5% NP-40. Viral copies were determined by Q-PCR or HA assay.
Onemillion viral particles of BKV subtypes I–IV and four variants were
denatured by boiling at 95 °C in SDS–polyacrylamide gel electropho-
resis (PAGE) sample buffer, and viral particles were separated by SDS–
10% PAGE and transferred to nylon-supported nitrocellulose
(Hybond-P; Amersham) overnight at 4 °C. Membranes were blocked
in Tris-buffered saline (TBS)–0.1% Tween 20 containing 10% non-fat
dry milk for 1 h and incubated for 2 h or overnight in 1x TBS–0.1%
Tween 20 containing 0.5% dry milk and antibody to SV40 VP1, which
cross-reacts with BK virus VP1 (pAb597; kindly provided by Walter
Atwood, Brown University). Proteins were visualized by using
horseradish peroxidase-conjugated secondary antibodies and the
ECL-Plus system (Amersham) followed by exposure to X-ray ﬁlm.
Quantitation of blots was performed by densitometry calculated as
relative intensity of regions of interest (ROI) using Photoshop. Results
were conﬁrmed a minimum of twice per viral isolate using at least
two different preparations of viral stocks.
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